Voyager Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $24,629 | $29,578 | $19,516 | $90,061 |
Gross Profit | 24,629 | -4,874 | 18,320 | 88,726 |
EBITDA | -12,648 | -13,633 | -14,987 | 55,398 |
EBIT | -13,780 | -15,025 | -16,183 | 54,063 |
Net Income | -9,044 | -10,141 | -11,330 | 56,395 |
Net Change In Cash | 24,629 | 29,578 | 19,516 | 90,061 |
Free Cash Flow | -28,226 | -32,547 | 56,626 | -26,617 |
Cash | 112,525 | 76,127 | 143,078 | 68,802 |
Basic Shares | 57,851 | 57,721 | 57,117 | 45,078 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $250,008 | $40,907 | $37,415 | $171,128 |
Gross Profit | 245,567 | 40,907 | 37,415 | 62,375 |
EBITDA | 126,455 | -44,646 | -68,453 | 31,201 |
EBIT | 122,014 | -50,837 | -73,618 | 27,384 |
Net Income | 132,330 | -46,408 | -66,032 | 36,741 |
Net Change In Cash | 250,008 | 40,907 | 37,415 | 171,128 |
Cost of Revenue | -18,738 | 12,993 | 19,442 | |
Free Cash Flow | 74,663 | -15,000 | -55,134 | -108,813 |
Cash | 68,802 | 98,959 | 117,433 | 104,440 |
Basic Shares | 44,569 | 38,356 | 37,668 | 37,348 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.16 |
2024-06-30 | -$0.18 |
2024-03-31 | -$0.20 |
2023-12-31 | $1.25 |
